SAB Biotherapeutics (SABS) Short Interest Ratio & Short Volume → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free SABS Stock Alerts $4.00 -0.10 (-2.44%) (As of 05/9/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media SAB Biotherapeutics Short Interest DataCurrent Short Volume25,600 sharesPrevious Short Volume28,900 sharesChange Vs. Previous Month-11.42%Dollar Volume Sold Short$111,616.00Short Interest Ratio / Days to Cover1.8Last Record DateApril 15, 2024Outstanding Shares9,230,000 sharesFloat Size7,480,000 sharesShort Percent of Float0.34%Today's Trading Volume4,012 sharesAverage Trading Volume13,811 sharesToday's Volume Vs. Average29% Short Selling SAB Biotherapeutics ? Sign up to receive the latest short interest report for SAB Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSABS Short Interest Over TimeSABS Days to Cover Over TimeSABS Percentage of Float Shorted Over Time Ad InvestorPlaceYou need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.Go here now for this breaking story. SAB Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202425,600 shares $111,616.00 -11.4%0.3%1.8 $4.36 3/31/202428,900 shares $131,206.00 +38.3%0.4%1.7 $4.54 3/15/202420,900 shares $115,368.00 -15.0%0.3%1.1 $5.52 2/29/202424,600 shares $109,716.00 -37.1%0.3%1.5 $4.46 2/15/202439,100 shares $217,005.00 +17.8%0.5%2.9 $5.55 1/31/202433,200 shares $199,200.00 +90.8%0.4%2.8 $6.00 Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/202417,400 shares $104,052.00 -2.8%0.2%1.5 $5.98 12/31/202317,900 shares $12,306.25 -91.4%N/A2.1 $0.69 12/15/2023207,600 shares $153,291.84 -11.2%0.3%3 $0.74 11/30/2023233,700 shares $227,156.40 +1.7%0.7%3.8 $0.97 11/15/2023229,800 shares $209,118.00 -12.1%0.6%4.4 $0.91 10/31/2023261,400 shares $261,373.86 -2.2%0.7%5.2 $1.00 10/15/2023267,200 shares $187,574.40 -2.8%0.7%6.4 $0.70 9/30/2023274,900 shares $173,187.00 -10.3%0.7%7.4 $0.63 9/15/2023306,500 shares $199,225.00 -17.5%0.8%8.5 $0.65 8/31/2023371,600 shares $267,552.00 +8.8%1.0%7 $0.72 8/15/2023341,500 shares $269,785.00 -12.3%0.9%5.9 $0.79 7/31/2023389,300 shares $315,333.00 -12.4%1.1%4.7 $0.81 7/15/2023444,400 shares $385,472.56 -4.1%1.3%1.6 $0.87 6/30/2023463,200 shares $384,456.00 +27.2%1.3%0.3 $0.83 6/15/2023364,300 shares $329,691.50 -14.9%1.0%0.3 $0.91 5/31/2023428,100 shares $381,009.00 -35.7%1.2%0.3 $0.89 5/15/2023665,400 shares $585,552.00 +28.3%1.9%0.5 $0.88 4/30/2023518,600 shares $465,858.38 +287.6%1.5%0.4 $0.90 4/15/2023133,800 shares $97,071.90 -3.2%0.4%0.1 $0.73 3/31/2023138,200 shares $60,808.00 -30.1%0.4%3.4 $0.44 3/15/2023197,800 shares $100,878.00 +17.5%0.6%4.3 $0.51 2/28/2023168,300 shares $109,395.00 +14.1%0.5%3.2 $0.65 2/15/2023147,500 shares $97,792.50 -2.8%0.5%2.7 $0.66 1/31/2023151,700 shares $103,064.98 +3.1%0.5%2.3 $0.68 1/15/2023147,100 shares $109,427.69 -14.4%0.5%2.1 $0.74 12/30/2022171,800 shares $101,344.82 -14.4%0.6%2.5 $0.59 12/15/2022200,700 shares $184,684.14 -6.1%0.7%2.8 $0.92 11/30/2022213,700 shares $230,796.00 -11.1%0.8%2.8 $1.08 11/15/2022240,300 shares $254,718.00 +8.2%0.9%3.1 $1.06 10/31/2022222,200 shares $199,980.00 -15.3%0.8%3.1 $0.90 10/15/2022262,400 shares $208,634.24 +7.7%0.9%3.8 $0.80 9/30/2022243,600 shares $170,763.60 +22.8%0.9%3.6 $0.70 9/15/2022198,300 shares $164,589.00 -22.1%0.7%3.6 $0.83 8/31/2022254,600 shares $178,245.46 +6.3%1.0%4.5 $0.70Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… SABS Short Interest - Frequently Asked Questions What is SAB Biotherapeutics' current short interest? Short interest is the volume of SAB Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 25,600 shares of SABS short. 0.34% of SAB Biotherapeutics' shares are currently sold short. Learn More on SAB Biotherapeutics' current short interest. What is a good short interest ratio for SAB Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SABS shares currently have a short interest ratio of 2.0. Learn More on SAB Biotherapeutics's short interest ratio. What is a good short interest percentage for SAB Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.34% of SAB Biotherapeutics' floating shares are currently sold short. Is SAB Biotherapeutics' short interest increasing or decreasing? SAB Biotherapeutics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 25,600 shares, a decline of 11.4% from the previous total of 28,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is SAB Biotherapeutics' float size? SAB Biotherapeutics currently has issued a total of 9,230,000 shares. Some of SAB Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. SAB Biotherapeutics currently has a public float of 7,480,000 shares. How does SAB Biotherapeutics' short interest compare to its competitors? 0.34% of SAB Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to SAB Biotherapeutics: Curis, Inc. (1.01%), Sangamo Therapeutics, Inc. (6.39%), Estrella Immunopharma, Inc. (0.05%), Quince Therapeutics, Inc. (6.21%), OKYO Pharma Limited (0.50%), Dyadic International, Inc. (0.92%), Achilles Therapeutics plc (0.10%), Protara Therapeutics, Inc. (4.35%), MiNK Therapeutics, Inc. (0.49%), Cyclo Therapeutics, Inc. (0.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short SAB Biotherapeutics stock? Short selling SABS is an investing strategy that aims to generate trading profit from SAB Biotherapeutics as its price is falling. SABS shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against SAB Biotherapeutics? A short squeeze for SAB Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SABS, which in turn drives the price of the stock up even further. How often is SAB Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SABS, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Curis Short Interest Data Sangamo Therapeutics Short Interest Data Estrella Immunopharma Short Interest Data Quince Therapeutics Short Interest Data OKYO Pharma Short Interest Data Dyadic International Short Interest Data Achilles Therapeutics Short Interest Data Protara Therapeutics Short Interest Data MiNK Therapeutics Short Interest Data Cyclo Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SABS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCharles Payne Demystifies OptionsUnstoppable Prosperity